- Mahindra Aerostructures Ltd has been awarded a contract by Airbus Helicopters to produce airframe parts for the AS565 MBe Panther military helicopter at its facility in Bengaluru, India. The parts will be shipped to Airbus' production line in France for assembly. - In 2015, Airbus and Mahindra's defense division had announced plans to form a joint venture to target India's military helicopter programs. - Cadila Healthcare Ltd announced that its US subsidiary Zydus Pharmaceuticals will begin informing customers on July 13, 2016 that it will launch an authorized generic version of Asacol HD in the United States starting August 1, 2016. - The benchmark S&P

1. SEBI Certified – Research Analyst www.choiceindia.com
Global View
India Update
Today’s Event/ Stock in News
Europe’s Airbus Helicopters has awarded a contract to Mahindra Aerostructures Ltd to make airframe parts for the AS565 MBe
Panther military chopper. The value of the contract was not disclosed by the companies. These parts will be produced at the
Mahindra facility in Bengaluru. “They will be shipped directly to the Airbus helicopter production line in Marignane, France where
theywillbeintegratedwiththe restoftheairframeassembly andwill formacriticalpartofthePantherssoldworldwide,”Mahindra
said in a statement. In July 2015, Airbus Helicopters and Mahindra’s defence division had said they are in the process of forming a
joint venture to target India’s military helicopter programmes such as the naval utility helicopter, the naval multi-role helicopter and
thereconnaissanceandsurveillancehelicopter.
Technical Outlook: Ondailychart,stock has givenpositivebreakoutof its rectangle formationinwhichit hadbeentradingformore
than two years. Moreover, stock has been continuously trading with its strong support of 21 day moving average which is placed at
1364 level, which shows that near term trend is up. A momentum indicator RSI reading is at 76.45 level with positive crossover,
which point out for positive breath in the stock. So for trading perspective, one could Buy in range of 1469-1476 for Target of 1506
withSLof1454.
M&M
CADILAHC
SEBI Registered – Research Analyst www.choiceindia.com * Please Refer Disclaimer on Website
Morning Tea
13th July 2016
Buy in range of 369-372 for Target of 380 with SL of 365
Buy in range of 1469-1476 for Target of 1506 with SL of 1454
Cadila Healthcare Limited has informed the Exchange that Cadila Healthcare Limited announced that its US based 100% subsidiary
companyZydusPharmaceuticals (USA) Inc. (Zydus)willbegininformingtodayitscustomersthatZyduswillstartsellinganauthorized
genericofAsacolHD(mesalaminedelayedreleasetablets800mg)intheUnitedStatescommencingonAugust1,2016.
Technical Outlook : On daily chart, stock has formed long leg of lower shadow candlestick which is a continuation candlestick and
indicates for further upside movement. Moreover, stock has managedto sustain above its 200 day moving average which is placed
at 352.70 level, which shows that long term trend has changed to up. A momentum indicator RSI reading is at 83.85 level with
positive crossover, which point out for positive breath inthe stock. So for trading perspective, one could Buy inrange of 369-372 for
Targetof380withSLof365.
The benchmark US S&P 500 stock index set record closing and intraday highs for the second straight day on Tuesday and the Dow
Jones industrial average reached record highs for the first time in over a year as optimism about the world economy and upbeat
corporate results from Alcoa boosted risk appetite. The benchmark S&P 500 ended at 2,152.14, topping Monday's record close of
2,137.16, while theDowclosed at 18,347.67totopits previous recordhightouchedinMay 2015. The S&P 500 hit a record intraday
peak of 2,155.40, while the Dow hit an intraday record of 18,371.95. The tech-heavy Nasdaq Composite also gained, wiping out its
lossesfortheyearandnotchingitshighestclosesincelateDecember.
Asian shares came within reach of testing their 2016 peak on Wednesday as prospects of solid US growth and accommodative
economic policy in major countries whet investors risk appetite damaged by uncertainty from Brexit. MSCI's broadest index of Asia-
PacificsharesoutsideJapanrose0.2percentinearlytradeto426.62,justbelowitsyear-to-datehighof428.22.Japan'sNikkeigained
1.9percent.TheIndianmarketislikelytoreactpositivelytostrongglobalcues.

2. SEBI Certified – Research Analyst www.choiceindia.com
Bulk Deal
SEBI Certified – Research Analyst www.choiceindia.com
Morning Tea
13th July 2016
Security in Ban
SEBI Registered – Research Analyst www.choiceindia.com * Please Refer Disclaimer on Website
Sr. No. Deal Date Script Code Security Name Client Name Deal Type Quantity Price
1 12/7/2016 533239 PRAKASHSTL PRAKASH CHAND SHARMA S 1148000 1.81
2 12/7/2016 514045 BSL INVESTOR INDIA LIMITED S 500111 82.75
3 12/7/2016 514045 BSL AKUNTH TEXTILE PROCESSORS PVT LTD B 500111 82.75
4 12/7/2016 517467 MARSONS CHARU KOTIA S 250000 14.01
5 12/7/2016 539331 VETO VETO ELECTROPOWERS INDIA PRIVATE LIMITED S 250000 135.00
6 12/7/2016 532972 SANKHYAIN IDBI BANK LIMITED S 149700 25.67
7 12/7/2016 504697 GALADA GOURAV KHANDELWAL S 122553 21.60
8 12/7/2016 504697 GALADA GOURAV KHANDELWAL B 122553 20.12
9 12/7/2016 531867 UNITINT AJAY SINGH HOODA S 113368 5.75
10 12/7/2016 533163 ARSSINFRA WAY2WEALTH SECURITIES P LTD S 102921 104.34
Corporate Action:
Kabra Extrusion Technik Limited; Annual General Meeting
Solar Industries India Limited; Fv Splt Frm Rs 10 To Rs 2
Hatsun Agro Product Limited; Bonus 2:5
Andhra Bank; Annual General Meeting/ Dividend - Re 0.50 Per Share
Ashok Leyland Limited; Annual General Meeting/Dividend Re 0.95 Per Share
Bharat Petroleum Corporation Limited; Bonus 1:1
CESC Limited; Annual General Meeting
Parrys Sugar Industries Limited; Annual General Meeting
R. S. Software (India) Limited; Annual General Meeting/ Dividend - Re 1/- Per Share
Phillips Carbon Black Limited; Annual General Meeting/Dividend -Rs 2.50 Per Share
Aarti Drugs Limited; Annual General Meeting
Chemfab Alkalis Limited; Dividend - Rs 1.25 Per Share
Plastiblends India Limited; Annual General Meeting
Result Calendar:
AQUAPIV, CUPID, INFOMEDIA, LGBFORGE, MNIL, NETWORK18, RIIL & TV18BRDCST
Corporate Action / Result Calendar
JPASSOCIAT

3. SEBI Certified – Research Analyst www.choiceindia.com
Contact Us
www.choiceindia.com
www.choiceindia.comcustomercare@choiceindia.com
Disclaimer
This is solely for information of clients of Choice Broking and does not construe to be an investment advice. It is also not intended as an offer or solicitation for the purchase and sale of any financial
instruments. Any action taken by you on the basis of the information contained herein is your responsibility alone and Choice Broking its subsidiaries or its employees or associates will not be liable in
any manner for the consequences of such action taken by you. We have exercised due diligence in checking the correctness and authenticity of the information contained in this recommendation, but
Choice Broking or any of its subsidiaries or associates or employees shall not be in any way responsible for any loss or damage that may arise to any person from any inadvertent error in the
information contained in this recommendation or any action taken on basis of this information. Technical analysis studies market psychology, price patterns and volume levels. It is used to forecast
future price and market movements. Technical analysis is complementary to fundamental analysis and news sources. The recommendations issued herewith might be contrary to recommendations
issued by Choice Broking in the company research undertaken as the recommendations stated in this report is derived purely from technical analysis. Choice Broking has based this document on
information obtained from sources it believes to be reliable but which it has not independently verified; Choice Broking makes no guarantee, representation or warranty and accepts no responsibility
or liability as to its accuracy or completeness. The opinions contained within the report are based upon publicly available information at the time of publication and are subject to change without
notice. The information and any disclosures provided herein are in summary form and have been prepared for informational purposes. The recommendations and suggested price levels are intended
purely for trading purposes. The recommendations are valid for the day of the report however trading trends and volumes might vary substantially on an intraday basis and the recommendations may
be subject to change. The information and any disclosures provided herein may be considered confidential. Any use, distribution, modification, copying, forwarding or disclosure by any person is
strictly prohibited. The information and any disclosures provided herein do not constitute a solicitation or offer to purchase or sell any security or other financial product or instrument. The current
performance may be unaudited. Past performance does not guarantee future returns. There can be no assurance that investments will achieve any targeted rates of return, and there is no guarantee
against the loss of your entire investment.
POTENTIAL CONFLICT OF INTEREST DISCLOSURE (as on date of report) Disclosure of interest statement – • Analyst interest of the stock /Instrument(s): - No. • Firm interest of the stock /
Instrument (s): - No.
SEBI Certified – Research Analyst www.choiceindia.com
Research Team
Mr. Sumeet Bagadia Associate Director
Kunal Parmar Research Associate
Amit Pathania Research Associate
Vikas Chaudhari Research Associate
Kapil Shah Research Associate
Rajnath Yadav Research Associate
Satish Kumar Research Associate
Morning Tea
13th July 2016
SEBI Registered – Research Analyst www.choiceindia.com * Please Refer Disclaimer on Website
Kunal Parmar
Digitally signed by Kunal Parmar
DN: cn=Kunal Parmar, o=Choice Equity Broking
Pvt Ltd., ou=Research Dept,
email=kunal.parmar@choiceindia.com, c=IN
Date: 2016.07.13 08:45:06 +05'30'